STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
Source: View publication →
The STAMPEDE trial is a landmark multi-arm, multi-stage platform study that has fundamentally reshaped the standard of care for men with high-risk, locally advanced, or metastatic hormone-naive prostate cancer by evaluating various systemic and local therapies.
Key Findings
Study Design
Study Limitations
Clinical Significance
The STAMPEDE platform has provided the evidence base to incorporate early docetaxel, abiraterone, and targeted primary radiotherapy into the standard management of hormone-sensitive prostate cancer, leading to improved long-term survival outcomes for patients.
Historical Context
Initiated in 2005 at the MRC Clinical Trials Unit, STAMPEDE pioneered the use of a MAMS platform design to efficiently evaluate multiple novel therapeutic combinations against a single contemporaneous control arm in a rapidly evolving field of prostate cancer care.
Guided Discussion
High-yield insights from every perspective
What is the physiological rationale for using Androgen Deprivation Therapy (ADT) as the foundational 'control' arm in the STAMPEDE trial for all stages of advanced prostate cancer?
Key Response
Prostate cancer is heavily dependent on the androgen receptor (AR) signaling pathway for growth and survival. By suppressing testosterone production via medical or surgical castration, the primary driver of tumor proliferation is inhibited. STAMPEDE uses ADT as the backbone therapy because it has been the standard of care since the work of Huggins and Hodges in the 1940s, providing a baseline against which the additive benefits of newer systemic agents or radiotherapy can be measured.
In patients with newly diagnosed metastatic hormone-naive prostate cancer (mHSPC), how did the STAMPEDE trial findings regarding the addition of docetaxel compare to the CHAARTED trial, particularly concerning metastatic volume?
Key Response
While the CHAARTED trial initially suggested a survival benefit for docetaxel primarily in 'high-volume' metastatic disease, the STAMPEDE trial demonstrated an overall survival benefit for docetaxel in the metastatic cohort regardless of tumor burden. This led to a broad recommendation for docetaxel plus ADT as a management option for all fit patients with mHSPC, though subsequent data and the 'STAMPEDE low-volume' analysis have since refined the preference for certain agents based on volume and patient comorbidities.
Analyze the STAMPEDE data regarding the use of radiotherapy to the primary prostate tumor in the setting of metastatic disease; which specific subgroup derives an overall survival benefit, and why is this clinically significant?
Key Response
STAMPEDE showed that local radiotherapy to the prostate improved overall survival (OS) only in patients with a low metastatic burden (defined by the CHAARTED criteria as fewer than 4 bone metastases and no visceral metastases), with a 3-year OS of 81% vs 73%. In high-burden disease, there was no OS benefit. This was a landmark finding because it proved that treating the primary 'seed' can alter the trajectory of systemic 'soil' in oligometastatic states, leading to the inclusion of local RT in guidelines for low-volume M1 disease.
The STAMPEDE trial demonstrated that adding Abiraterone to ADT improved survival in metastatic disease, but the combination of Abiraterone and Enzalutamide did not further improve outcomes over Abiraterone alone. How does this impact your approach to treatment sequencing and 'intensification' in practice?
Key Response
The comparison of Arm J (Abiraterone + Enzalutamide) versus the contemporaneous control showed no survival advantage for the combination but significantly higher toxicity. This teaches that simultaneous dual AR-axis blockade does not overcome resistance more effectively than single-agent intensification. In practice, this reinforces the 'less is more' approach regarding toxicity—choosing one potent AR-targeted agent (Abiraterone or Enzalutamide) rather than both, and saving subsequent agents for sequential use at the time of castration resistance.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The STAMPEDE trial utilizes a Multi-Arm Multi-Stage (MAMS) platform design. Discuss how the use of an intermediate primary endpoint, such as Failure-Free Survival (FFS), affects the statistical power and efficiency of the trial when deciding which arms to graduate to the final Overall Survival (OS) analysis.
Key Response
The MAMS design uses FFS (a composite of PSA failure, progression, or death) as a 'futility' filter. If an arm does not show a pre-specified level of benefit in FFS during the internal pilot stages, it is discontinued. This allows for rapid testing of multiple agents simultaneously using a shared control arm, reducing the total sample size required compared to separate Phase III trials. However, it requires a high correlation between the intermediate endpoint and the final endpoint (OS) to ensure that potentially beneficial treatments are not prematurely discarded.
A major criticism of platform trials like STAMPEDE is the 'drifting control arm.' How should reviewers critically evaluate the internal validity of comparisons made between arms that were recruited during non-overlapping or only partially overlapping time periods?
Key Response
As the Standard of Care (SOC) evolves (e.g., the transition from ADT-alone to ADT+Docetaxel as SOC), the control group changes. Comparing an experimental arm from 2015 to a control group from 2005 is invalid due to changes in imaging (e.g., PSMA-PET), supportive care, and subsequent lines of therapy. Editors look for 'contemporaneous' control comparisons—ensuring that the patients in the control arm were randomized at the same time as those in the experimental arm to account for temporal biases in clinical practice.
How do the results of the STAMPEDE 'M0' (non-metastatic) analysis for Abiraterone plus ADT compare to current NCCN/EAU guidelines for high-risk locally advanced prostate cancer?
Key Response
The STAMPEDE M0 analysis showed that for very high-risk non-metastatic patients (node-positive or meeting specific high-risk criteria), the addition of 2 years of Abiraterone to ADT and RT significantly improved metastasis-free survival (MFS) and OS (HR 0.60 for death). Consequently, guidelines (e.g., EAU) were updated to include Abiraterone for 2 years as a Level 1 recommendation for men with high-risk/very high-risk M0 disease, shifting the paradigm from 'RT + ADT' to 'RT + ADT + Abiraterone'.
Clinical Landscape
Noteworthy Related Trials
CHAARTED Trial
Tested
Docetaxel plus androgen-deprivation therapy (ADT)
Population
Men with metastatic hormone-sensitive prostate cancer
Comparator
Androgen-deprivation therapy (ADT) alone
Endpoint
Overall survival
LATITUDE Trial
Tested
Abiraterone acetate plus prednisone and ADT
Population
Patients with high-risk metastatic hormone-sensitive prostate cancer
Comparator
ADT plus placebo
Endpoint
Overall survival and radiographic progression-free survival
ARCHES Trial
Tested
Enzalutamide plus ADT
Population
Men with metastatic hormone-sensitive prostate cancer
Comparator
Placebo plus ADT
Endpoint
Radiographic progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis